Dose Arm 1 for Chronic Kidney Disease (CKD)
Phase-Based Progress Estimates
Effectiveness
Safety
Mayo Clinic Florida, Jacksonville, FL
Chronic Kidney Disease (CKD)+2 More
Allogeneic adipose-derived mesenchymal stem cells (MSC) - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
The purpose of this study is to assess the safety and tolerability of intravenously delivered mesenchymal steml cells (MSC) in one of two fixed dosing regimens at two time points in patients with chronic kidney disease.
Eligible Conditions
- Chronic Kidney Disease (CKD)
Treatment Effectiveness
Effectiveness Progress
Other trials for Chronic Kidney Disease (CKD)
Study Objectives
2 Primary · 0 Secondary · Reporting Duration: 15 months
15 months
Adverse events and/or serious adverse events
6 months
Change in eGFR Value
Trial Safety
Safety Progress
Other trials for Chronic Kidney Disease (CKD)
Trial Design
2 Treatment Groups
Dose Arm 1
1 of 2
Dose Arm 2
1 of 2
Experimental Treatment
20 Total Participants · 2 Treatment Groups
Primary Treatment: Dose Arm 1 · No Placebo Group · Phase 1
Dose Arm 1
Drug
Experimental Group · 1 Intervention: Allogeneic adipose-derived mesenchymal stem cells (MSC) · Intervention Types: DrugDose Arm 2
Drug
Experimental Group · 1 Intervention: Allogeneic adipose-derived mesenchymal stem cells (MSC) · Intervention Types: DrugTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 15 months
Closest Location: Mayo Clinic Florida · Jacksonville, FL
2007First Recorded Clinical Trial
2 TrialsResearching Chronic Kidney Disease (CKD)
86 CompletedClinical Trials
Eligibility Criteria
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have an eGFR of 25-55 ml/min/1.73m2.
Albumin:creatinine ratio ≥300 mg/g or proteinuria ≥300 mg/day despite maximally tolerated dose of RAAS drugs (e.g
Hemoglobin A1c of ≤ 8% despite maximally tolerated anti-diabetes therapy.
You have the ability to give informed consent.\n
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments